CellViva Appoints Three Ophthalmology Leaders to Board of Directors

CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors.

According to CellViva, the new directors are:

• Adrienne Graves, PhD, who is former Board Chair of Iveric Bio. Dr. Graves brings decades of experience in clinical development and strategic leadership within the ophthalmology sector.
• Kathryn Najafi-Tagol, MD, who is Founder of the Eye Institute of Marin in San Rafael, California. She is co-inventor of Avenova, a treatment for dry eye associated with blepharitis. Additionally, she is former Chief Medical Officer of NovaBay Pharmaceuticals. Dr. Najafi brings extensive clinical and pharmaceutical development experience.
• Richard Lindstrom, MD, a cataract and refractive surgeon, who is founder of Minnesota Eye Consultants in Minneapolis, Minnesota. Dr. Lindstrom offers a wealth of knowledge in surgical innovations and industry expertise.

“We are thrilled to welcome Drs. Graves, Najafi, and Lindstrom to our Board of Directors,” commented CellViva’s Board Chair, President. and CEO Randal Pham in the company’s press release. “Their combined knowledge and experience in ophthalmology will be pivotal as we advance our mission to develop a groundbreaking treatment for pterygium.”